Las acciones de Abbott subieron la madrugada del miércoles debido a métricas "entrecortadas" del tercer trimestre.

Abbott Laboratories will separate its global nutrition business into an independently traded company by the end of 2027, creating a $8.5…

Abbott Laboratories (NYSE:ABT) informó un crecimiento de las ventas del tercer trimestre del 7 % y un crecimiento de las ganancias ajustadas por acción del 9 %, al tiempo que anunció planes para separar su negocio de nutrición en una empresa independiente que cotiza en bolsa mediante una distribución libre de impuestos a los accionistas. Presidente y director ejecutivo

Abbott, which also cut its 2026 sales growth guidance, said company sales will total $42 billion following the separation.

Abbott Laboratories plans to spin off its nutrition business into a separate company – a move that follows years of tumult over its infant formulas. The new business will sell Abbott products including Similac, PediaSure, Pedialyte, Glucerna and Ensure. The company also makes medical tests, medical devices and generic pharmaceuticals. The new company is expected to have $8.5 billion in annual ...

Abbott reports Q3 2026 revenue of $13.01 billion and adjusted EPS of $1.42, alongside plans to spin off its Nutrition business by late 2027.

Abbott Laboratories planea escindir su negocio de nutrición en una empresa separada, una medida que sigue a años de tumulto en torno a sus fórmulas infantiles.

Abbott Laboratories will separate its nutrition business into an independent, publicly traded company via a tax-free spin-off by the end of 2027, CEO…

Abbott Laboratories (ABT) disclosed plans on Wednesday to separate its nutrition business into a pub